Abstract
Rasagiline mesylate (RM) used as first-line agent for Parkinsonism exhibit low oral-bioavailability and extensive hepatic first-pass metabolism requires frequent administration. Polymeric nanoparticles of this hydrophilic drug (RM-NPs) were developed to enhance its systemic concentration and BBB crossing capacity and characterized for particle size, zeta potential; entrapment efficiency. Ex-vivo permeation study was conducted to analyze solvent-system for increased permeation of RM across biological membrane which revealed RM showed maximum flux (96.66 ± 4.63 µg/cm2/h) at 8.36 ± 0.39h with 33% propylene glycol–ethanol while RM-NPs in distilled water showed 94.16 ± 3.62 µg/cm2/h flux at 6.80 ± 0.31h indicating that 33% propylene glycol–ethanol can serve as solvent-of-choice for transdermal delivery of rasagiline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Polymeric Materials and Polymeric Biomaterials
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
